CASE STUDY

MilliporeSigma

Differentiating on Risk vs. Opportunity in Global Biopharma

Insights • Message strategy • Campaign development

Challenge

MilliporeSigma had spent years advancing their portfolio in monoclonal antibody bioproduction, aiming to stay ahead in the industry. But they soon encountered a challenge—other competitors had achieved similar milestones, making it harder to stand out.

Insight

The Biopharma industry is highly concerned about and preoccupied with risk.

Solution

Instead of touting ‘end-to-end’ offerings, affirm the company’s commitment to partner with biopharma to mitigate unprecedented risks of globalization, biosimilars and virtual biotech companies.

SIMILAR CASE STUDIES

READY TO BEGIN?

We’re ready to hear about your challenges and empower your success.